How are energy investors positioned?
Gillespie Geoffrey C, Chief Accounting Officer at Orthofix Medical (TASE:BLWV) Inc. (NASDAQ:OFIX), a medical device company with annual revenues of $799 million and a market capitalization of $572 million, recently sold 76 shares of the company’s common stock. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 2.57. The shares were sold at a price of $15.74 each, amounting to a total transaction value of $1,196. This sale was conducted to satisfy tax withholding obligations related to the settlement of restricted stock units, as mandated by the company’s Compensation and Talent Development Committee. Following this transaction, Gillespie retains ownership of 42,445 shares. InvestingPro analysis indicates the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report, which offers detailed analysis of this and 1,400+ other US stocks.
In other recent news, Orthofix International reported fourth-quarter earnings with revenue reaching $215.7 million, surpassing the consensus estimate of $212.4 million. The company’s EBITDA also exceeded expectations, coming in at $23.9 million. Despite these positive results, Orthofix’s revenue guidance for 2025 fell short of analyst projections, estimating between $818 million and $826 million compared to a projected $847 million. This adjustment reflects the discontinuation of certain product lines, which previously contributed significantly to revenue. Additionally, Orthofix received FDA 510(k) clearance and a European CE Mark for its TrueLok Elevate Transverse Bone Transport System, marking a significant development in its product offerings.
The company also announced the appointment of Vickie Capps to its Board of Directors, bringing her extensive finance expertise to the team. Analyst firms have weighed in on Orthofix’s performance, with Citizens JMP maintaining a Market Perform rating and BTIG holding a Neutral rating. Meanwhile, Canaccord Genuity initiated coverage with a Buy rating, citing the company’s strategic initiatives and product portfolio. These developments indicate Orthofix’s ongoing focus on innovation and strategic growth within the medical technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.